PART I Overview We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy ...
Q2 FY2026 — expected 2026-08-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001628280-26-017242 | EDGAR | 104K words |
| 2025-03-13 | 2024-12-31 | 0001737287-25-000036 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0001737287-24-000021 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001737287-23-000018 | EDGAR | — |
| 2022-02-23 | 2021-12-31 | 0001737287-22-000013 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001737287-21-000009 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001737287-20-000012 | EDGAR | — |
| 2019-03-08 | 2018-12-31 | 0001564590-19-006991 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001628280-25-050230 | EDGAR | 63K words |
| 2025-08-13 | 2025-06-30 | 0001737287-25-000088 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001737287-25-000064 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001737287-24-000073 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001737287-24-000056 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001737287-24-000041 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001737287-23-000091 | EDGAR | — |
| 2023-08-02 | 2023-06-30 | 0001737287-23-000076 | EDGAR | — |
| 2023-05-03 | 2023-03-31 | 0001737287-23-000053 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0001737287-22-000083 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001737287-22-000067 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0001737287-22-000035 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001628280-26-017230 | EDGAR | 2K words |
| 2025-11-06 | 0001628280-25-050227 | EDGAR | — |
| 2025-10-14 | 0001628280-25-044828 | EDGAR | — |
| 2025-08-13 | 0001737287-25-000087 | EDGAR | — |
| 2025-08-01 | 0001193125-25-171091 | EDGAR | — |
| 2025-06-23 | 0001737287-25-000070 | EDGAR | — |
| 2025-05-13 | 0001737287-25-000063 | EDGAR | — |
| 2025-03-13 | 0001737287-25-000035 | EDGAR | — |
| 2025-02-25 | 0001193125-25-035162 | EDGAR | — |
| 2025-01-29 | 0001193125-25-014985 | EDGAR | — |
125 total filings indexed. 95 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001737287 |
| Ticker | ALLO |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.allogene.com |
| Listed | 2018-10-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report